Krishnan Viswanadhan Sells 2,959 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Krishnan Viswanadhan sold 2,959 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the transaction, the insider directly owned 5,141 shares of the company’s stock, valued at approximately $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $28.26 on Wednesday. The stock’s 50 day moving average price is $28.10 and its 200 day moving average price is $33.07. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The company has a market cap of $1.66 billion, a PE ratio of -3.97 and a beta of 0.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth about $183,000. Seven Fleet Capital Management LP purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $864,000. T. Rowe Price Investment Management Inc. purchased a new position in Agios Pharmaceuticals during the 4th quarter valued at about $25,000. Invesco Ltd. raised its position in Agios Pharmaceuticals by 12.3% during the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock worth $3,881,000 after acquiring an additional 15,604 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Agios Pharmaceuticals during the fourth quarter worth about $1,253,000.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on AGIO. JPMorgan Chase & Co. upped their price target on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, December 29th. Truist Financial boosted their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Leerink Partners upped their target price on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, December 26th. Finally, The Goldman Sachs Group dropped their target price on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday, November 20th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has an average rating of “Hold” and an average price target of $40.67.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.